← All Verrica Pharmaceuticals INC filings

Verrica Pharmaceuticals INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
VRCA
Verrica Pharmaceuticals INC
10-K: Verrica Pharmaceuticals Reports FY2024 Results, Navigates Financial Uncertainty
Verrica Pharmaceuticals announces its FY2024 results, highlighting YCANTH sales growth while acknowledging substantial doubt about its ability to continue as a going concern.
NASDAQ
VRCA
Verrica Pharmaceuticals INC
10-K: Verrica Pharmaceuticals Reports Full Year 2023 Results, Highlights YCANTH Launch and Pipeline Progress
Verrica Pharmaceuticals' 2023 annual report details the commercial launch of YCANTH for molluscum contagiosum, ongoing clinical trials, and financial results including a net loss of $67 million.